Xarelto generics aren’t the only threat Bayer is facing to one of its high-selling drugs. Biosimilar copycats to blockbuster eye med Eylea are looming, but, with a recently approved high-dose ...
Health News // 8 years ago Some increased bleeding risk seen with blood thinner Xarelto vs. Pradaxa The blood thinner Xarelto may pose a slightly greater risk of serious bleeding than Pradaxa in ...
Dabigatran etexilate (Pradaxa; Boehringer Ingelheim ... competition soon from other OACs in development, in particular rivaroxaban (Xarelto; Bayer/Johnson & Johnson). Rivaroxaban, which is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback